Latest Articles

Publication Date
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive

Published: April 12, 2026, 12:58 a.m.
Mesentery-Preserving Hand-Sewn Anastomosis for Rectal Endometriosis: A Nerve-Sparing Laparoscopic Technique.

To describe a mesentery-preserving, nerve-sparing laparoscopic technique for rectal endometriosis.

Published: April 12, 2026, midnight
Endometrial NCOR1 deficiency contributes to implantation failure in endometriosis-associated infertility.

Endometriosis-associated infertility is a complex condition in which the presence of endometrial-like tissue disrupts implantation and early pregnancy. Epigenetic regulators are critical for implantation and decidualization, yet their contribution to …

Published: April 12, 2026, midnight
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today

Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer Cure Today

Published: April 11, 2026, 9:14 p.m.
Ray-Ban Meta deal: Save 25% on smart AI glasses at Amazon - Mashable

Ray-Ban Meta deal: Save 25% on smart AI glasses at Amazon Mashable

Published: April 11, 2026, 8:13 p.m.
Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork

Black Women With Endometrial Cancer Completed Treatment More With Peer Support CancerNetwork

Published: April 11, 2026, 8:04 p.m.
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive

Published: April 11, 2026, 6:14 p.m.
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative

BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative

Published: April 11, 2026, 11:10 a.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!